Events

Join PCRI at The 2019 Moyad + Scholz Mid-Year Update on March 30, 2019. The conference will be held at the LAX Marriott, and will feature incredible presentations from the most esteemed doctors in prostate cancer! Speakers are Kirk Wojno, MD, Tanya Dorff, MD, Mark Moyad, MD, MPH, & Mark Scholz, MD. Topics include Genetic Testing, Hormone Therapies, Imaging, & Advanced Treatments from A-Z. You don’t want to miss this highly informative and supportive event. This conference is an awesome opportunity to learn about advancements in the prostate cancer field, to connect with other patients and caregivers, and to gain crucial knowledge so you can make the best decisions for your health. We look forward to seeing you in March!

The term “prostate cancer” is an umbrella term that covers five major stages and 15 subtypes. It is not a singular disease. There are distinct varieties.

People often mistakenly assume that the different ways prostate cancer behaves—life threatening vs. benign—are due to seeing the same illness at different time points. In reality, distinct varieties of prostate cancer exist. It’s not all the same disease. The clinical stage and the pathologic stage are important, but it’s not the whole picture.

What’s overlooked, often with disastrous consequences, is that these differences are also due to the fact that distinct varieties of prostate cancer exist. Receiving optimal therapy depends on matching an appropriate treatment with both the correct stage and the correct type of prostate cancer.

The term “prostate cancer” is an umbrella term that covers five major stages and 15 subtypes. It is not a singular disease. There are distinct varieties.

People often mistakenly assume that the different ways prostate cancer behaves—life threatening vs. benign—are due to seeing the same illness at different time points. In reality, distinct varieties of prostate cancer exist. It’s not all the same disease. The clinical stage and the pathologic stage are important, but it’s not the whole picture.

What’s overlooked, often with disastrous consequences, is that these differences are also due to the fact that distinct varieties of prostate cancer exist. Receiving optimal therapy depends on matching an appropriate treatment with both the correct stage and the correct type of prostate cancer.